眾生藥業(002317.SZ):目前新冠藥來瑞特韋片可以在部分醫療終端、互聯網醫院及線上平台經問診後購買
格隆匯5月12日丨眾生藥業(002317.SZ)於2023年5月10日10:00-12:00接受機構調研,問答環節中,就“來瑞特韋片項目介紹。”,公司回覆稱,公司口服單藥抗新冠病毒3CL蛋白酶抑制劑來瑞特韋片已獲得由國家藥物監督管理局按照藥品特別審批程序應急審評審批,附條件批准上市,用於治療輕中度新型冠狀病毒感染(COVID-19)的成年患者。
來瑞特韋片不需要聯合肝藥酶抑制劑(CYP酶抑制劑)利托那韋,單藥治療即可顯著縮短新冠感染患者的臨牀恢復時間,顯著降低病毒載量,避免聯合利托那韋用藥可能產生的臨牀限制和安全性風險,為老年及合併基礎疾病等不能使用或限制使用利托那韋的新冠病毒感染患者提供可選擇的治療藥物。作為中國首款具有自主知識產權的3CL單藥抗新冠病毒1類創新藥物,來瑞特韋片的成功上市,有望為新冠感染患者帶來更多的治療選擇,是公司創新轉型的重要里程碑。
公司持續拓展多種銷售渠道,目前來瑞特韋片可以在部分醫療終端、互聯網醫院以及線上平台(如美團、天貓)經問診後購買。公司密切關注疾病動態情況,及時做好藥品生產和配送工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.